- Home
- QNRX
as 11-15-2024 4:00pm EST
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | KFAR SABA |
| Market Cap: | 2.1M | IPO Year: | N/A |
| Target Price: | $4.00 | AVG Volume (30 days): | 486.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.64 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.48 - $6.18 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Quoin Pharmaceuticals Ltd. (QNRX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Dunn Gordon | QNRX | Chief Financial Officer | Sep 9 '24 | Buy | $0.80 | 28,856 | $23,204.80 | 18,856 | |
| Myers Michael | QNRX | Chief Executive Officer | Sep 3 '24 | Buy | $0.71 | 37,894 | $28,916.10 | 10,158 | |
| Carter Denise P. | QNRX | Chief Operating Officer | Sep 3 '24 | Buy | $0.71 | 37,735 | $28,737.13 | 47,092 |
Latest Quoin Pharmaceuticals Ltd. News
QNRX Breaking Stock News: Dive into QNRX Ticker-Specific Updates for Smart Investing
Zacks Small Cap Research
6 days ago
QNRX: International Sites Participating in QRX003 NS Study, Studying QRX003 for Additional Diseases, in Younger Populations
GlobeNewswire
11 days ago
Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2024 Financial Results
GlobeNewswire
13 days ago
Quoin Pharmaceuticals Initiates Clinical Testing of Lead Product in Pediatric Netherton Syndrome Patient
GlobeNewswire
18 days ago
Quoin Pharmaceuticals to Announce Third Quarter 2024 Financial Results on Thursday, November 7, 2024
GlobeNewswire
a month ago
Quoin Pharmaceuticals Announces Further International Expansion of Ongoing Clinical Trials for Netherton Syndrome
GlobeNewswire
2 months ago
Quoin Pharmaceuticals Announces Insider Share Purchases by Co-Founders CEO and COO
Zacks Small Cap Research
3 months ago
QNRX: Assessing QRX003 For Multiple Conditions; Opening International Netherton Syndrome Clinical Sites
GlobeNewswire
3 months ago
Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2024 Financial Results
Compare QNRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "QNRX Quoin Pharmaceuticals Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.